There are 2789 resources available
588P - Androgen changes after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial
Presenter: Klara Kvorning Ternov
Session: ePoster Display
589P - Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Enrique Perez Navarro
Session: ePoster Display
648TiP - PSMAfore: A phase III study to compare <sup>177</sup>Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC
Presenter: Michael Morris
Session: ePoster Display
475P - A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)
Presenter: Jordan Berlin
Session: ePoster Display
650TiP - PARADIGM: Plasma analysis for response assessment and to direct the management of metastatic prostate cancer (mPCa)
Presenter: Anuradha Jayaram
Session: ePoster Display
660P - Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
Presenter: Toni Choueiri
Session: ePoster Display
597P - A phase I dose-escalation study of LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Dingwei Ye
Session: ePoster Display
598P - A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Jimmy Zhao
Session: ePoster Display
599P - A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment
Presenter: Alberto Bessudo
Session: ePoster Display